Advertisement

Advertisement
Howard I. Scher, MD, on Prostate Cancer: Circulating Tumor Cells as a Surrogate Endpoint for Survival

Howard I. Scher, MD, on Prostate Cancer: Circulating Tumor Cells as a Surrogate Endpoint for Survival

Nivolumab Combined With Ipilimumab Shows Activity in Prostate Cancer Subsets

Nivolumab Combined With Ipilimumab Shows Activity in Prostate Cancer Subsets

In contrast with melanoma, lung cancer, and kidney cancer, immune checkpoint inhibitor therapy has been disappointing in prostate cancer thus far. Because of success in treating...

Enzalutamide Plus ADT Extends Progression-Free Survival in Metastatic Hormone-Sensitive Prostate Cancer

Enzalutamide Plus ADT Extends Progression-Free Survival in Metastatic Hormone-Sensitive Prostate Cancer

Adding enzalutamide to androgen-deprivation therapy (ADT) significantly prolonged radiographic progression-free survival in men with metastatic hormone-sensitive...

CheckMate 650: Nivolumab and Ipilimumab in Metastatic, Castration-Resistant Prostate Cancer

CheckMate 650: Nivolumab and Ipilimumab in Metastatic, Castration-Resistant Prostate Cancer

SOME PATIENTS with metastatic prostate cancer may respond to a combination of immune checkpoint inhibitors after treatment with hormonal therapy...

SBRT vs Conventionally Fractionated, or Moderately Hypofractionated External-Beam Radiotherapy, for Localized Prostate Cancer

SBRT vs Conventionally Fractionated, or Moderately Hypofractionated External-Beam Radiotherapy, for Localized Prostate Cancer

TREATMENT WITH stereotactic body radiation therapy (SBRT) results in a similar safety profile to conventionally fractionated, or moderately hypofractionated...

Advertisement


Advertisement